The dermatopharmacologic profile of ciclopirox 8% nail lacquer

Journal of the American Podiatric Medical Association

Volumn 90, Issue 10, 2000, Pages 491-494

  Bonn, Manfred ^a   Kraemer, Karl ^b  

^a SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; CICLOPIROX; PYRIDONE DERIVATIVE;

ANIMAL; ARTICLE; HUMAN; IN VITRO STUDY; METABOLISM; NAIL; ONYCHOMYCOSIS; SKIN DISEASE; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANIMALS; ANTIFUNGAL AGENTS; FOOT DERMATOSES; HUMANS; NAILS; ONYCHOMYCOSIS; PYRIDONES;

EID: 0034328162     PISSN: 87507315     EISSN: None     Source Type: Journal    
DOI: 10.7547/87507315-90-10-491     Document Type: Article

References (10)

1. CHIRITESCU MM, CHIRITESCU M, SCHER R: Newer systemic antifungal drugs for the treatment of onychomycosis. Clin Podiatr Med Surg 13: 741, 1996.
2. ELEWSKI B, HAY R: Update on the management of onychomycosis: highlights of the Third Annual International Summit on Cutaneous Antifungal Therapy. Clin Infect Dis 23: 305, 1996.
3. ELEWSKI BE: Once-weekly fluconazole in the treatment of onychomycosis: introduction. J Am Acad Dermatol 38: S73, 1998.
4. ELEWSKI B, CHARIF M, DANIEL CI: "Onychomycosis," in Nails: Diagnosis, Treatment, Surgery, 2nd Ed, ed by R Scher, CI Daniel, p 151, WB Saunders, Philadelphia, 1997.
5. SAKURAI K, SAKAGUCHI T, YAMAGUCHI H, ET AL: Mode of action of 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone ethanolamine salt (Hoe 296). Chemotherapy 24: 68, 1978.
6. SAKURAI K, SAKAGUCHI T, YAMAGUCHI H, ET AL: Studies on uptake of 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone ethanolamine salt (Hoe 296) by Candida albicans. Chemotherapy 24: 146, 1978.
7. BRAGA PC, PIATTI G, CONTI E, ET AL: Effects of subinhibitory concentrations of ciclopirox on the adherence of Candida albicans to human buccal and vaginal epithelial cells. Arzneimittelforschung 42: 1368, 1992.
8. JUE SG, DAWSON G, BROGDEN R: Ciclopirox olamine 1% cream: a preliminary review of its antimicrobial activity and therapeutic use. Drugs 29: 330, 1985.
9. Penlac, "Integrated Summary of Efficacy" [data on file], Dermik Laboratories, Collegeville, PA, 1998.
10. TOSTI A, PIRACCINI B, LORENZI S: Onychomycosis caused by nondermatophytic molds: clinical features and response to treatment of 59 cases. J Am Acad Dermatol 42: 217, 2000.